問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

Chung Shan Medical University Hospital (在職)

Division of Rheumatology

Dalin Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation (在職)

Division of Rheumatology

Division of Dermatology

Hualien Tzu Chi Hospital (在職)
National Taiwan University Hospital Hsin-Chu Branch

Division of Rheumatology

更新時間：2023-09-19

吳政翰WU, CHENG-HAN
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳政翰

List

68Cases

2020-07-13 - 2024-04-30

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2021-01-31 - 2024-04-30

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Not yet recruiting4Sites

2019-07-19 - 2022-01-01

Phase II

Completed
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    NA

Participate Sites
6Sites

Recruiting6Sites

2018-12-20 - 2030-01-31

Phase III

Active
A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    Risankizumab

Participate Sites
3Sites

Terminated3Sites

黃毓惠
Linkou Chang Gung Medical Foundation

2019-10-31 - 2023-10-05

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-11-12 - 2030-12-19

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-07-31 - 2024-02-06

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2016-04-01 - 2020-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated3Sites

藍忠亮
China Medical University Hospital-Taipei

未分科

2021-10-01 - 2023-08-04

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-08-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

張棋楨
Taipei Medical University Hospital

Division of Rheumatology

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB